Concurrent Investment Advisors LLC Has $36.09 Million Stock Position in Merck & Co., Inc. $MRK

Key Points

• Concurrent Investment Advisors increased its Merck stake by 10.5% in the second quarter, adding 26,733 shares to hold 280,871 shares valued at approximately $36.1 million. Institutional investors collectively own 76.07% of Merck.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while revenue rose 5.1% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $147.60.
• Merck declared a quarterly dividend of $0.85 per share, equivalent to an annualized $3.40 and a 2.2% yield. However, insiders sold roughly $30.0 million of company stock over the past 90 days.

Concurrent Investment Advisors LLC increased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 10.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 280,871 shares of the company's stock after purchasing an additional 26,733 shares during the period. Concurrent Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $36,092,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. High Note Wealth LLC boosted its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Insider Buying and Selling

In related news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David Williams sold 52,847 shares of the business's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last ninety days. Insiders own 0.17% of the company's stock.

Merck & Co., Inc. Price Performance

MRK stock opened at $152.32 on Friday. The company has a 50 day simple moving average of $134.20 and a 200 day simple moving average of $123.33. The stock has a market cap of $375.80 billion, a price-to-earnings ratio of 121.86, a P/E/G ratio of 6.60 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 EPS. The firm's revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. BMO Capital Markets raised their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an "outperform" rating in a report on Thursday, August 20th. Weiss Ratings upgraded Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 25th. Scotiabank boosted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a report on Tuesday, June 30th. Finally, Jefferies Financial Group downgraded Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $147.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source